Alnylam Pharmaceuticals, Inc. vs Abbvie Inc.
ALNY vs ABBV — side-by-side comparison from reported financials. ALNY leads 5, ABBV leads 5 of 10 comparable metrics.
Alnylam Pharmaceuticals, Inc.
ALNY · Healthcare
$232.60+3.59%Strong
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | ALNY | ABBV |
|---|---|---|
| Price | $232.60 | $276.43 |
| Market cap | $31.1B | $488B |
| Revenue (TTM) | $4.80B | $64.4B |
| Revenue growth | +53.0% | +1.8% |
| Net margin | 16.8% | 9.8% |
| Free cash flow | $794M | $18.2B |
| Net cash (debt) | — | ($56.2B) |
| 1-year price return | -49.1% | +19.8% |
| P/E | 38.5 | 77.4 |
| P/E vs own history (cheap-side %) | 92% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 94% | 96% |
| Altman Z-score | 4.40 | 2.33 |
| CV checks passed | 8 of 10 | 9 of 10 |
| Employees | 2,500 | 57,000 |
Full résumé-style profiles: ALNY CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.